Barrington analyst Michael Petusky maintained a Buy rating on Anika Therapeutics Inc (ANIK) today and set a price target of $44. The company’s shares closed yesterday at $40.49.
Petusky observed:
“We are maintaining our OUTPERFORM investment rating on ANIK shares but are reducing our price target to $44 (from $49 previously). The likely absence of a previously expected $5 million MONOVISC milestone payment is the primary driver behind our price reduction. We arrive at our price target by attaching a 14x multiple to our 2019 adjusted EBITDA estimate. We assume around $182 million in net cash 12 months from now.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 6.9% and a 53.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and Lemaitre Vascular.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anika Therapeutics Inc with a $40.50 average price target.
See today’s analyst top recommended stocks >>
Anika Therapeutics Inc’s market cap is currently $575.4M and has a P/E ratio of 31.63. The company has a Price to Book ratio of 2.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.
